Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical (Nasdaq: MBOT) has commenced the full market release (FMR) in the U.S. of its LIBERTY® Endovascular Robotic System after a successful limited market release (LMR).
LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures and has been adopted by leading systems including Emory Healthcare and Tampa General Hospital. The system has been used commercially for PAE, UFE, GAE, Y90 mapping and deliveries, and peripheral arterial interventions. Commercial footprint expanded from 4 to 8 sales territories with a goal of 12 territories by end of 2026.
Microbot Medical (Nasdaq: MBOT) announced that Emory Healthcare completed the first robotic Prostatic Artery Embolization (PAE) and the first robotic Y-90 radioembolization mapping using the LIBERTY® Endovascular Robotic System on March 26, 2026. The single-use, FDA-cleared LIBERTY system aims to improve precision, reduce radiation exposure, and expand access to peripheral endovascular care. Microbot began a Limited Market Release in November 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026 to deepen clinical adoption.
Microbot Medical (NASDAQ: MBOT) announced publication of the ACCESS-PVI pivotal study in the Journal of Vascular and Interventional Radiology on March 24, 2026. The multicenter feasibility study completed in 2025 and underwent independent peer review. The LIBERTY system received FDA clearance in September 2025 and had a limited market release in late 2025, with a planned full market release at the SIR conference in April 2026.
The publication strengthens the clinical evidence base supporting broader commercial adoption of the single-use LIBERTY endovascular robotic system.
Microbot Medical (Nasdaq: MBOT) will present at the 38th Annual Roth Conference March 22-24, 2026, with a live webcast fireside Q&A on March 23, 2026 at 4:00 pm PT. CEO Harel Gadot will discuss LIBERTY commercial progress, limited market release traction, and plans for a full market release in April 2026 at SIR.
The webcast is available via the company’s Investors site and the presentation aims to showcase product differentiation, physician safety benefits, and upcoming commercialization steps.
Microbot Medical (Nasdaq: MBOT) will participate for the first time in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, March 16-19, 2026.
CEO Harel Gadot will present a live webcast on March 19 at 8:40 am ET highlighting LIBERTY® limited market release progress, clinical experience, and growth drivers ahead of a planned full market release at SIR in April 2026.
Microbot Medical (Nasdaq: MBOT) endorsed the American Medical Association’s late-2025 policy expanding protections against occupational ionizing radiation. The company highlights its LIBERTY Endovascular Robotic System as a safety solution: ACCESS-PVI showed a 92% relative reduction in radiation exposure. LIBERTY is FDA-cleared, single-use, remotely operated, entered a Limited Market Release in late 2025, and aims for a Full Market Release at SIR in April 2026.
The system also enables seated operation away from radiation, reducing reliance on heavy PPE and musculoskeletal strain for providers.
Microbot Medical (Nasdaq: MBOT) confirms no business disruption in the U.S. or Israel amid current geopolitical events and says employee safety is the top priority. The company says internal operations and its lead manufacturing partner remain fully functional, with sufficient U.S. inventory to support customers.
Following FDA clearance, Microbot began a limited market release of the LIBERTY Endovascular Robotic System in late 2025 and plans a full market release at the SIR conference in April 2026. The company is expanding U.S. commercial infrastructure with new sales hires and a Director of HEOR, and is building additional U.S. stock via a third-party logistics partner.
Microbot Medical (Nasdaq: MBOT) announced Tampa General Hospital is the first health system in Florida to adopt the LIBERTY® Endovascular Robotic System following the Company's recent FDA 510(k) clearance. The limited market release began in late 2025, with a planned full market release at the Society of Interventional Radiology conference in April 2026.
LIBERTY is described as the only FDA‑cleared, single‑use, remotely operated robotic system for peripheral endovascular procedures, aiming to improve navigation precision and reduce radiation and ergonomic strain.
Microbot Medical (Nasdaq: MBOT) announced that CEO Harel Gadot will be a featured panelist at The Surgical Disruptive Technology Summit during SAGES NBT Innovation Weekend, Feb 19-21, 2026, in Houston.
The session Endovascular Therapeutics: AI and Robotics will showcase the LIBERTY Endovascular Robotic System, its single-use remote operation, and planned full market release at SIR in April 2026.
Microbot Medical (NASDAQ: MBOT) highlighted its LIBERTY Endovascular Robotic System at the International Symposium on Endovascular Therapy (ISET), Feb 9-12, 2026, where experts discussed single-use robotic solutions.
The company noted LIBERTY's FDA clearance, limited market release begun in late 2025, cross-specialty hospital use, and plans for a full market release at SIR in April 2026.